Instrument Inactif

Autres langues JHL Biotech, Inc.

Actions

6540

KYG7863U1076

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Bora Pharmaceutical Laboratories Inc. acquired CDMO Assets of JHL Biotech, Inc. for $100 million.	10/05/22
First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar	18/05/20
JHL Biotech, Inc. Announces First Patient Randomized in the Phase Iii Study of JHL1101 to Treat Diffuse Large B-Cell Lymphoma	27/12/18
JHL Biotech, Inc. Announces China Approves Phase I and Phase III Clinical Trial Application for Bevacizumab Biosimilar to Treat Cancer	15/10/18
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer	10/08/18
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Rituximab Biosimilar	09/07/18
Jhl Biotech Announces China Approves Clinical Trial Rituximab Biosimilar to Treat Non-Hodgkin Lymphoma	05/07/18
JHL Biotech, Inc. Appoints Ellis Chu as Chief Financial Officer	13/06/18
JHL Biotech, Inc. announced that it has received $106 million in funding from a group of investors	15/05/18
JHL Biotech Seeks Financing	30/03/18
JHL Biotech, Inc. Announces European Authority, Bulgarian Drug Agency Approves Phase I Clinical Trial Application	22/02/18
JHL Biotech, Inc.(GTSM:6540) dropped from S&P Global BMI Index	12/02/18
JHL Biotech, Inc.'s Board intends to launch an Equity Buyback.	05/02/18
JHL Biotech, Inc. announced that it expects to receive $150 million in funding	16/01/18
JHL Biotech, Inc. Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis	20/12/17
JHL Biotech Submits Clinical Trial Application in Europe for Proposed Bevacizumab Biosimilar to Treat Colorectal, Lung, and Ovarian Cancers	20/12/17
JHL Biotech Inc Announces Its Clinical Trial Application for Use of JHL1101 in Phase 1 and Phase 3 Clinical Trials	05/04/17
JHL Doses First Patient In JHL1101 Phase I European Trial	29/03/17
Sanofi Enters into Strategic Biologics Alliance with JHL Biotech in China	05/12/16
JHL Biotech, Inc. announced that it expects to receive TWD 2.55 billion in funding from Sanofi	05/12/16

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues JHL Biotech, Inc.

Actions

6540

KYG7863U1076

Autres langues

Filtres